Plain-English translation of NCT06987916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called U01 (), which uses specially modified immune cells to fight B-cell lymphoma — a type of blood cancer. The key innovation is that this medication includes technology designed to reduce dangerous side effects that can occur with similar immune cell therapies by blocking a harmful chemical called IL-6. Researchers want to see if this treatment is safe and effective for people whose lymphoma has stopped responding to standard drugs or has come back.
Current immune cell therapies for lymphoma can cause serious side effects when the body's immune system becomes overactive. This medication was designed to address this problem by silencing the gene responsible for producing the harmful chemical that drives these dangerous reactions, potentially making the treatment safer while keeping it effective.
You likely qualify if…
You likely don't qualify if…
You would have blood cells collected through a process called leukapheresis, which are then modified in the laboratory and given back to you as an infusion. You would be closely monitored during and after the infusion for side effects, with regular visits to assess how well the treatment is working. The study will evaluate your safety, any side effects, and whether your lymphoma responds to this new medication.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Enrollment target
~50 participants
Started
April 2025
Primary completion
April 2028
Age range
2 Years – 75 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenjun Zhang, Doctor
Tongji hospital of tongji university (Shanghai tongji hospital)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.